Proxy Results, Amendments to Bylaws, Management Change/Compensation (Form 8-K)

The 2026 Annual Meeting of Stockholders (the "Annual Meeting") of Inhibikase Therapeutics, Inc. (the "Company") was held on June 26, 2026 in a virtual-only format via live webcast. As further described in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the Company's stockholders approved an amendment to the Company's 2020 Equity Incentive Plan to increase the authorized number of shares of common stock reserved for issuance by 3,000,000 shares (the "2020 Plan Amendment"). A summary of the 2020 Plan Amendment was contained in the Company's definitive proxy statement (the "Proxy Statement") filed on April 30, 2026 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended, and is incorporated herein by reference. The 2020 Plan Amendment was previously approved by the Company's board of directors, subject to approval by the Company's stockholders.

The foregoing description of the 2020 Plan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the 2020 Plan Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K, and incorporated herein by reference.

As further described in Item 5.07 to this Current Report on Form 8-K, at the Annual Meeting, the Company's stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") to limit the liability of certain officers of the Company as permitted by Delaware law. A summary of the Certificate of Amendment was contained in the Proxy Statement and is incorporated herein by reference. The Certificate of Amendment was previously approved by the Company's board of directors, subject to approval by the Company's stockholders.

On June 26, 2026, the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective upon filing.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated herein by reference.

The Annual Meeting was held on June 26, 2026. The following proposals were approved at the Annual Meeting by the votes indicated:

Proposal One: To elect two Class III directors, Arvind Kush and Dennis Berman, to the Board of Directors, each to serve until the Company's 2029 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.

Arvind Kush and Dennis Berman were duly elected to the Board of Directors as Class III directors, each to serve until the Company's 2029 annual meeting of stockholders, or until his successor is duly elected and qualified, or until his earlier death, resignation or removal:

Proposal Two: To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Proposal Three: To approve an amendment to the Company's certificate of incorporation to limit the liability of certain officers of the Company as permitted by Delaware law.

Proposal Four: To approve an amendment to the Company's 2020 Equity Incentive Plan to increase the authorized number of shares of common stock reserved for issuance by 3,000,000 shares.

Proposal Five: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

Proposal Six: To vote, on a non-binding, advisory basis, on the frequency of future non-binding, advisory votes on compensation of the Company's named executive officers.

Based on these voting results, and the recommendation of the Board that was included in the Proxy Statement, the Company has determined that it will hold future advisory votes on the compensation of the Company's named executive officers on an annual basis until the next stockholder advisory vote on the frequency of future votes on the compensation of the Company's named executive officers.

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.